Effects of asparaginases and L-carnitine on Western-diet-induced hepatosteatosis in mice
-
Published:2022-02-01
Issue:
Volume:11
Page:128
-
ISSN:2046-1402
-
Container-title:F1000Research
-
language:en
-
Short-container-title:F1000Res
Author:
Ali Mahmoud Assar MonaORCID,
Hüffel Martina,
Afify Mamdouh,
Weiskirchen RalfORCID,
Eisert Albrecht,
Tolba Rene,
Steitz JuliaORCID
Abstract
Abstract Background: Asparaginases are common chemotherapeutic agents used for the treatment of acute lymphoblastic leukemia as a single or combinational therapy. Accompanying hepatotoxicity makes its use in elderly patients with pre-conditions, as obesity or other hepatopathies, difficult. Various hepatoprotective compounds like, L-carnitine, are discussed to ameliorate the induced hepatotoxicity. Methods: Here we aimed to establish a mouse model to study the effect of asparaginases (L-asparaginase and Oncaspar) and L-carnitine on Western-diet-induced hepatosteatosis in mice. Dose-escalation studies were performed to analyze asparaginases induced hepatotoxicity in C57BL/6 mice with normal or fatty livers. Subsequently, the effect of L-carnitine to improve the induced toxicity was tested. Results: Our results showed mild-to-moderate hepatotoxic effects while the Western-diet induced a higher degree of vacuolization and hepatocyte damage in liver tissue. Testing of L-carnitine in the established models did not show any protective effect on the toxicity or impairment of the efficacy of asparaginases. Conclusion: The here established models were able to demonstrate the asparaginase-induced hepatotoxic effects which were enhanced by the Western-diet. However, to test potential ameliorating drugs, the models might need some improvements.
Funder
This work was supported with a stipend to Mona Ali Mahmoud Assar by the Egyptian cultural affairs and missions’ sector and ministry of higher education
European Union and NRW government
Publisher
F1000 Research Ltd
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference41 articles.
1. Asparaginase (native ASNase or pegylasted ASNase) in the treatment of acute lymphoblastic leukemia.;V Avramis;Int. J. Nanomedicine.,2006
2. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.;R Pieters,2011
3. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.;V Avramis;Blood.,2002
4. Enzyme therapy: L-asparaginase.;B Chabner,1990
5. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.;M Earl;Clin. Adv. Hematol. Oncol.,2009